Clinical-Browse

Result: 61 - 80 of 96

DownLoad :

FASTA

HTML

XLS

XML

DRAMP ID	NAME	Description	Medical_use	Stage of development	Company
DRAMP18173	Pediocin PA-1 (Bacteriocin)	Pediococcus acidilactici UL5	Gastrointestinal tract infections; Stomach and intestine infections (Murine model; In-vivo)	Preclinical	Unknown
DRAMP18174	Nisin A (Type A lantibiotic)	Lactococcus lactis subsp	Urogenital tract infections; Spermicidal activity (Rabbit model; In-vivo)	Preclinical	Unknown
DRAMP18175	Bac8c	Synthetic derivative of bactenecin from bovine neutrophils	Staphylococus aureusanti-infectives	Preclinical	Unknown
DRAMP18176	Temporin10a	Frog (Rana ornativentris) skin	Staphylococus aureusanti-infectives	Preclinical	Unknown
DRAMP18177	Syphaxin(SPX1-22)	Frog (Leptodactylus syphax) skin	Staphylococus aureusanti-infectives	Preclinical	Unknown
DRAMP18178	IDR-1	IDR-1 is a 13-amino acid peptide derived from bovine neutrophils that shows antimicrobial activity against MRSA, VRE, and other Gram-positive and Gram-negative pathogens.	Prevention of infections in the immune compromised	Phase I	Unknown
DRAMP18179	IDR-1002	Derivative of bactenecin from bovine neutrophils	Staphylococus aureusanti-infectives	Preclinical	Unknown
DRAMP18180	Buforin II	Asian Toad (Bufo bufo gargarizans) stomach	Staphylococus aureusanti-infectives	Preclinical	Unknown
DRAMP20773	Dusquetide(SGX942)	Dusquetide is a synthetic, 5-amino acid peptide and Innate Defense Regulator (IDR), with immunomodulating, anti-inflammatory, anti-infective and anti-mucositis activities. Upon intravenous administration, dusquetide binds to the ZZ domain of sequestosome-1, also called p62, and activates regulatory signaling transduction pathways involved in the modulation of the innate immune system, such as those mediated by mitogen-activated protein kinase (MAPK) p38 and CCAAT-enhancer-binding protein. This agent promotes monocyte and macrophage recruitment to, and accelerates healing in damaged and infected tissue; it suppresses inflammation through the regulation of the expression of multiple cytokines. This agent may prevent or decrease chemo- or radiotherapy-induced mucositis as well as other types of infection. p62, an intracellular adaptor protein that functions downstream of certain signaling receptors, plays a key role in the activation of the innate immune system.	Treatment for oral complications caused by radiation therapy for head and neck cancer.	Phase III	Soligenix
DRAMP20760	C16G2	a synthetic AMP	Treatment of Adult and Adolescent Dental Subjects	Phase II	Lantibio
DRAMP18181	DP178 (T20, Enfuvirtide & Fuzeon)	Enfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake. The first agent in the novel class of antiretroviral drugs called HIV fusion inhibitors, enfuvirtide works by inhibiting HIV-1 fusion with CD4 cells.	Human Immunodeficiency Virus (HIV) Infections; AIDS	Proved by FDA	Trimeris
DRAMP18182	Sifuvirtide (SFT)	designed based on the 3D structure of the HIV-1 gp41 fusogenic core conformation	HIV fusion inhibitor;AIDS	Phase II	Unknown
DRAMP18183	SB006 (M6)	tetra-branched multimeric form of the linear sequence	Gram-negative infections	Preclinical	SpiderBiotech
DRAMP20761	LTX-109	LTX-109 is a broad-spectrum, fast-acting bactericidal antimicrobial drug for topical treatment, which causes membrane disruption and cell lysis.	Uncomplicated Gram positive skin infections, impetigo,and nasal colonization with S. aureus	Phase I/II	Lytix Biopharma AS
DRAMP20774	Murepavadin (POL7080)	synthetic by amino acid substitution of protegrin I.	Treatment of nosocomial pneumonia and ventilator-associated bacterial pneumonia (VABP)	Phase III(suspended, adverse events)	Polyphor Ltd.
DRAMP18160	Omiganan (MBI-226/MX-226/CLS001)	Omiganan (MBI-226), an analogue of indolicidin, has been proven to be capable of significantly reducing catheter colonization and microbiologically confirmed tunnel infections during catheterization	Rosacea, Acne vulgaris (II), Genital warts (II)	Phase III(catheter-related infections,Failure), Phase III(rosacea, completed), Phase II(atopic dermatitis (AD), usual type vulval intraepithelial neoplasia (uVIN), external genital warts, and acne vulgaris, completed), Phase III(facial seborrheic dermatitis, recruiting)	Maruho Co., Ltd(developing), Cutanea Life Sciences, Inc.(developing), Mallinckrodt, Micrologix Biotech(Vancouver, BC, Canada)
DRAMP28983	PL-5	This product is a national category 1 anti-infective innovation category in China, and has obtained PCT US and Chinese invention patent authorizations. Suitable for skin and wound infections, especially for stubborn infectious diseases caused by drug-resistant bacteria, against traditional antibiotics, "super bacteria" Pseudomonas aeruginosa, and methicillin-resistant Staphylococcus aureus (MRSA) and multi-drug resistant Acinetobacter baumannii containing NDM-1 gene have very strong bactericidal advantages. Its preparation antimicrobial peptide PL-5 spray is the first antimicrobial peptide variety to enter clinical research in my country, and this product has also been supported by the National Health and Family Planning Commission’s 12th and 13th Five-Year "Major New Drug Development" projects. Phase I clinical research has been completed, and Phase II clinical research is currently underway.	Skin wound infection	Phase IIIb	Changchun ProteLight Pharmaceutical & Biotechnology Co.
DRAMP29315	Bacitracin	Bacitracin A is a homodetic cyclic peptide consisting of (4R)-2-[(1S,2S)-1-amino-2-methylbutyl]-4,5-dihydro-1,3-thiazole-4-carboxylic acid attached head-to-tail to L-leucyl,D-glutamyl, L-lysyl, D-ornityl, L-isoleucyl, D-phenylalanyl, L-histidyl. D-aspartyl and L-asparaginyl residues coupled in sequence and cyclised by condensation of the side-chain amino group of the L-lysyl residue with the C-terminal carboxylic acid group. It is the major component of bacitracin. It has a role as an antibacterial agent and an antimicrobial agent. It is a homodetic cyclic peptide and a polypeptide.	prevent wound infections, treat pneumonia and empyema in infants, and to treat skin and eye infections.	In market
DRAMP29316	Surotomycin(MK-4261/CB-183,315)	Surotomycin has been used in trials studying the treatment of Diarrhea and Clostridium Difficile Infection. It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections. Surotomycin has a fourfold greater in vitro potency than vancomycin against C. Difficile and other Gram-positive bacteria with minimal impact on the Gram-negative organisms of the intestinal microbiota. Surotomycin, given orally, has been shown to be highly effective against both initial and relapsing hamster Clostridium difficile-associated diarrhea, with a potency similar to vancomycin. Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection.	Treatment of Diarrhea and Clostridium Difficile Infection	Phase III	Cubist Pharmaceuticals Inc./Merck & Co. Inc.
DRAMP29317	Colistin(polymyxin-E)	Colistin is a polymyxin antibiotic used to treat bacterial infections caused by susceptible Gram negative bacteria.	Treatment of acute or chronic infections due to sensitive strains of certain gram-negative bacilli, particularly Pseudomonas aeruginosa.	In market